Articles tagged with B Cell Receptor Signaling
Researchers at MD Anderson Cancer Center presented findings on novel treatments for MDS, including luspatercept, which significantly reduced the need for blood transfusions in lower-risk patients. Additionally, a triplet therapy regimen improved survival in older adults with FLT3-mutated AML.
Researchers describe redundant innate immune pathways triggered by AAV vectors, including sensing of viral genome and cytoplasmic DNA sensors. The study highlights the need to understand complex biologic mechanisms underlying adverse reactions to AAV vectors in human gene therapy trials.
Researchers have designed a novel Co-STAR receptor that combines genetic components of four types of immune cells to recognize and fight cancer cells. In laboratory studies, the Co-STAR receptor induced a sustained anti-tumor response against human cancer cells, leading to long-lasting remissions in mouse models.
Researchers from Osaka University found that Csk inhibits germinal center B cell signaling, decreasing reactive oxygen species production and promoting affinity maturation. This study reveals the crucial role of Csk tyrosine kinase in regulating B cell development.
Researchers developed novel therapeutic bispecific antibodies targeting IgM and B-cell surface antigens, which directly inhibited cell proliferation via cell-cycle arrest and apoptosis in vitro. These findings suggest that anti-IgM/B-cell surface antigen-binding specific antibodies are promising therapeutic agents for B-cell malignancies.
Researchers identified TLR9 as a key receptor in central tolerance, the process that eliminates self-reactive B cells. Depleting TLR9 impairs this process, leading to increased antibody production and autoimmune disease. Neutralizing CXCL4 may restore B cell tolerance, offering new therapeutic strategies.
Researchers at Weill Cornell Medicine discovered a new relationship between cancer cells and the immune system, showing how prolonged activation of the STING pathway leads to cellular signaling changes that aid cancer's spread. This finding explains why drugs activating STING have been unsuccessful in clinical trials.
Researchers report an updated analysis from a phase I study of mivavotinib, a spleen tyrosine kinase inhibitor, in patients with relapsed/refractory B-cell lymphoma. The study showed a 45% overall response rate and median duration of response of 28.1 months in the overall cohort.
Scientists have elucidated the exact molecular structure of an IgM-type B cell receptor, revealing its asymmetrical complex with signaling subunits. The discovery provides insights into how the receptor interacts with other molecules and could lead to a better understanding of vaccine development and lymphoma formation.
CD22 paradoxically augments BCR signaling by upregulating BCR expression, restoring B cell function in immunodeficient cells. High levels of BCR are required for survival, and CD22 facilitates this process.
Researchers at The Wistar Institute discovered that CLL cells downregulate STING protein to allow for increased expression of B cell receptors on their surface, promoting survival. This reduction in STING expression enables stronger B cell receptor signaling, supporting CLL cell survival.
A comprehensive profile of B cells in rheumatoid arthritis reveals their involvement in the disease's progression. Researchers identified two specific differences in B cells that contribute to the condition, including the inclusion of interleukin 15 receptor subunit alpha and high levels of amphiregulin.
Scientists identified a mechanism of resistance to ibrutinib, a current treatment for non-Hodgkin lymphoma, and discovered a promising therapeutic target in three enzymes. Blocking these enzymes with masitinib completely ablated the B-cell receptor pro-tumorigenic signals.
A recent study published in the Journal of Experimental Medicine reveals that a common CLL treatment may be less effective in patients with a specific protein marker. Combining ibrutinib with drugs blocking this protein could prevent tumor cells from sheltering in lymphoid organs, leading to improved patient outcomes.
A new mouse model reveals that the B-cell receptor cooperates with MYC oncogene to accelerate lymphoma development. Disruption of B-cell receptor signals can inhibit tumor growth, suggesting potential therapeutic targets.